A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years

Vaccine

Volumn 31, Issue 34, 2013, Pages 3452-3460

  Nelson, E Anthony S ^a   Lam, Hugh Simon ^a   Choi, Kai C ^a   Ho, Wendy C S ^a   Fung, L W Eva ^a   Cheng, Frankie W T ^a   Sung, Rita Y T ^a   Royals, Michael ^b   Chan, Paul K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b PharmaJet Inc   (United States)

Author keywords

Human papillomavirus; Intradermal; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEELING UNWELL; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; JET INJECTION; NEEDLE; NORMAL HUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SKIN DISCOLORATION; SKIN REDNESS; SYRINGE; VACCINATION;

EID: 84880515012     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.034     Document Type: Article

References (20)

1. Arbyn M., Castellsague X., de Sanjose S., Bruni L., Saraiya M., Bray F., et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22(12):2675-2686.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
3. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(July (9686)):301-314.
4. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med 2007, 356(May (19)):1915-1927. FUTURE II Study Group.
5. Lambert P.H., Laurent P.E. Intradermal vaccine delivery: will new delivery systems transform vaccine administration?. Vaccine 2008, 26(June (26)):3197-3208.
6. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. New Engl J Med 2004, 351(November (22)):2286-2294.
7. Sangare L., Manhart L., Zehrung D., Wang C.C. Intradermal hepatitis B vaccination: a systematic review and meta-analysis. Vaccine 2009, 27(March (12)):1777-1786.
8. Fabrizi F., Dixit V., Magnini M., Elli A., Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Therap 2006, 24(August (3)):497-506.
9. Wu A., Zeng Q., Kang T.H., Peng S., Roosinovich E., Pai S.I., et al. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther 2011, 18(3):304-312.
10. van den Hende M., van Poelgeest M.I.E., van der Hulst J.M., de Jong J., Drijfhout J.W., Fleuren G.J., et al. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. Int J Cancer 2008, 123(1):146-152.
11. Hung C.F., Monie A., Alvarez R.D., Wu T.C. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007, 39(6):679-689.
12. Egemen A., Aksit S., Kurugol Z., Erensoy S., Bilgic A., Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine 1998, 16(October (16)):1511-1515.
13. Kurugol Z., Erensoy S., Aksit S., Egemen A., Bilgic A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study. Vaccine 2001, 19(July (28-29)):3936-3939.
14. Arnou R., Icardi G., De D.M., Ambrozaitis A., Kazek M.P., Weber F., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27(December (52)):7304-7312.
15. Buck C.B., Pastrana D.V., Lowy D.R., Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. Journal of Virology 2004, 78(January (2)):751-757.
16. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321(April (2)):205-216.
17. Glenn G.M., Kenney R.T. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol 2006, 304:247-268.
18. Vogelbruch M., Nuss B., Korner M., Kapp A., Kiehl P., Bohm W. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 2000, 55(9):883-887.
19. Young F., Marra F. A systematic review of intradermal influenza vaccines. Vaccine 2011, 29(48):8788-8801.
20. Nelson K.S., Janssen J.M., Troy S.B., Maldonado Y. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine 2012, 30(2):121-125.